Carboplatin doxorubicin versus cisplatin doxorubicin cyclophosphamide randomized trial stage III-IV epithelial ovarian carcinoma sixty-four patients stage III-IV epithelial ovarian carcinoma cisplatin CDDP mg/mq mg/mq mg/mq PAC mg/mq mg/mq CAC equitoxic doses cycle drug dosages hematologic toxicities previous course CAC PAC patients dosage reduction second course CAC PAC relevant neuro-nephrotoxicity CDDP hydration forced diuresis carboplatin rapid intravenous IV infusion cycles response rates superimposable CAC PAC pathologic complete responses pCRs CAC PAC patients cm residual disease PAC pCRs CAC Median survivals progression-free survivals PFSs months PAC months CAC differences significant conclusion trial equitoxic doses PAC CAC result similar response rate PFS survival 